Medexus Pharmaceuticals IncTSX:MDPView on OTCQX International
- LAST PRICE2.1300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.1000/ 12
- Ask / Lots2.1300/ 18
- Open / Previous Close2.1300 / 2.1300
- Day Range
- 52 Week Range
- Volume500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | MDP |
|---|---|---|
| 09:32 ET | 500 | 2.13 |
Nov 20, 2024
DJ Medexus Pharmaceuticals Inc Price Target Raised to C$4.00/Share From C$3.00 by Raymond James, from 11:46AM ET on Wednesday Nov 20, 2024 by Dow Jones
11:46AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Nov 7, 2024
Medexus Announces Strong Fiscal Q2 2025 Results, from 5:32PM ET on Thursday Nov 07, 2024 by Dow Jones
5:32PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 29, 2024
Medexus Schedules Second Fiscal Quarter 2025 Conference Call, from 5:02PM ET on Tuesday Oct 29, 2024 by Dow Jones
5:02PM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medexus Pharmaceuticals Inc | 52.5M | 16.3x | --- |
Vireo Growth Inc | 70.8M | -3.2x | --- |
Simply Better Brands Corp | 78.8M | -2.2x | --- |
Acreage Holdings Inc | 11.5M | -0.2x | --- |
Vext Science Inc | 34.2M | -4.3x | -33.20% |
Innocan Pharma Corp | 62.9M | -16.6x | --- |
Company Information
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Contact Information
- Headquarters
- 10 King Street East, Suite 600TORONTO, ON, Canada M5C 1C3
- Phone
- 514-762-2626
- Fax
- ---
Executives
- Independent Chairman of the Board
- Michael Mueller
- Director
- Ken D'entremont
- Chief Financial Officer
- Brendon Buschman
- General Counsel, Corporate Secretary
- Ian Wildgoose Brown
- General Manager, Canadian Operations
- Richard Labelle
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.5M |
|---|---|
Revenue (TTM) | $146.3M |
Shares Outstanding | 24.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.91 |
EPS | $0.13 |
Book Value | $1.73 |
P/E Ratio | 16.3x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | 4.6x |
Operating Margin | 7.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
